DDInter1881 DDInter704
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Lipoic acid {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is upregulated by {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Pericardial effusion {u} (Side Effect) is caused by {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Mirabegron {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Cytochrome P450 2D6 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Everolimus
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Raltegravir {u} (Compound) downregulates {v} (Gene) INPP1
INPP1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid (Compound) binds POR (Gene) and POR (Gene) is upregulated by Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) causes Pericardial effusion (Side Effect) and Pericardial effusion (Side Effect) is caused by Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) and Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) includes Everolimus (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir (Compound) downregulates INPP1 (Gene) and INPP1 (Gene) is downregulated by Everolimus (Compound)